Annual Total Expenses
$10.11 B
+$1.23 B+13.80%
December 31, 2024
Summary
- As of February 18, 2025, REGN annual total expenses is $10.11 billion, with the most recent change of +$1.23 billion (+13.80%) on December 31, 2024.
- During the last 3 years, REGN annual total expenses has risen by +$3.03 billion (+42.86%).
- REGN annual total expenses is now at all-time high.
Performance
REGN Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Expenses
$2.79 B
+$300.20 M+12.08%
December 31, 2024
Summary
- As of February 18, 2025, REGN quarterly total expenses is $2.79 billion, with the most recent change of +$300.20 million (+12.08%) on December 31, 2024.
- Over the past year, REGN quarterly total expenses has increased by +$353.80 million (+14.55%).
- REGN quarterly total expenses is now at all-time high.
Performance
REGN Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
REGN Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +13.8% | +14.6% |
| 3 y3 years | +42.9% | +14.6% |
| 5 y5 years | +132.5% | +14.6% |
REGN Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +42.9% | at high | +79.7% |
| 5 y | 5-year | at high | +132.5% | at high | +146.9% |
| alltime | all time | at high | >+9999.0% | at high | +883.5% |
Regeneron Pharmaceuticals Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $10.11 B(+13.8%) | $2.79 B(+12.1%) |
| Sep 2024 | - | $2.48 B(+1.3%) |
| Jun 2024 | - | $2.45 B(+2.8%) |
| Mar 2024 | - | $2.39 B(-1.8%) |
| Dec 2023 | $8.88 B(+23.8%) | $2.43 B(+13.0%) |
| Sep 2023 | - | $2.15 B(+0.5%) |
| Jun 2023 | - | $2.14 B(-0.8%) |
| Mar 2023 | - | $2.16 B(-3.5%) |
| Dec 2022 | $7.18 B(+1.4%) | $2.24 B(+30.7%) |
| Sep 2022 | - | $1.71 B(+10.5%) |
| Jun 2022 | - | $1.55 B(-7.6%) |
| Mar 2022 | - | $1.68 B(-25.9%) |
| Dec 2021 | $7.08 B(+43.8%) | $2.26 B(+41.0%) |
| Sep 2021 | - | $1.61 B(-10.4%) |
| Jun 2021 | - | $1.79 B(+26.5%) |
| Mar 2021 | - | $1.42 B(+12.7%) |
| Dec 2020 | $4.92 B(+13.2%) | $1.26 B(+1.2%) |
| Sep 2020 | - | $1.24 B(-4.2%) |
| Jun 2020 | - | $1.30 B(+14.8%) |
| Mar 2020 | - | $1.13 B(-5.0%) |
| Dec 2019 | $4.35 B(+66.5%) | $1.19 B(+18.2%) |
| Sep 2019 | - | $1.01 B(-20.4%) |
| Jun 2019 | - | $1.26 B(+41.4%) |
| Mar 2019 | - | $892.60 M(-351.1%) |
| Dec 2018 | $2.61 B(-31.2%) | -$355.50 M(-134.3%) |
| Sep 2018 | - | $1.04 B(+5.2%) |
| Jun 2018 | - | $985.80 M(+4.4%) |
| Mar 2018 | - | $944.30 M(-9.5%) |
| Dec 2017 | $3.79 B(+7.4%) | $1.04 B(+10.9%) |
| Sep 2017 | - | $940.75 M(+2.3%) |
| Jun 2017 | - | $919.80 M(+3.5%) |
| Mar 2017 | - | $888.45 M(+1.0%) |
| Dec 2016 | $3.53 B(+23.8%) | $879.84 M(+2.6%) |
| Sep 2016 | - | $857.32 M(-6.9%) |
| Jun 2016 | - | $921.00 M(+5.7%) |
| Mar 2016 | - | $871.54 M(+0.5%) |
| Dec 2015 | $2.85 B(+42.9%) | $867.00 M(+16.4%) |
| Sep 2015 | - | $745.00 M(+14.0%) |
| Jun 2015 | - | $653.76 M(+11.6%) |
| Mar 2015 | - | $586.06 M(-0.1%) |
| Dec 2014 | $2.00 B(+46.6%) | $586.53 M(+9.2%) |
| Sep 2014 | - | $537.32 M(+22.8%) |
| Jun 2014 | - | $437.61 M(+0.8%) |
| Mar 2014 | - | $434.18 M(+4.5%) |
| Dec 2013 | $1.36 B(+47.9%) | $415.32 M(+15.3%) |
| Sep 2013 | - | $360.23 M(+20.3%) |
| Jun 2013 | - | $299.54 M(+4.5%) |
| Mar 2013 | - | $286.61 M(+6.6%) |
| Dec 2012 | $920.76 M(+41.4%) | $268.93 M(+19.4%) |
| Sep 2012 | - | $225.32 M(+3.9%) |
| Jun 2012 | - | $216.92 M(+3.5%) |
| Mar 2012 | - | $209.59 M(+24.5%) |
| Dec 2011 | $650.98 M(+17.0%) | $168.38 M(+4.4%) |
| Sep 2011 | - | $161.29 M(-4.1%) |
| Jun 2011 | - | $168.13 M(+9.8%) |
| Mar 2011 | - | $153.19 M(+4.6%) |
| Dec 2010 | $556.55 M(+22.8%) | $146.45 M(+6.1%) |
| Sep 2010 | - | $138.07 M(-1.1%) |
| Jun 2010 | - | $139.61 M(+5.4%) |
| Mar 2010 | - | $132.41 M(-2.8%) |
| Dec 2009 | $453.37 M(+39.6%) | $136.21 M(+14.7%) |
| Sep 2009 | - | $118.75 M(+11.7%) |
| Jun 2009 | - | $106.30 M(+15.4%) |
| Mar 2009 | - | $92.12 M(+6.1%) |
| Dec 2008 | $324.71 M(+35.6%) | $86.86 M(+1.6%) |
| Sep 2008 | - | $85.52 M(+6.5%) |
| Jun 2008 | - | $80.27 M(+11.0%) |
| Mar 2008 | - | $72.29 M(-5.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2007 | $239.48 M(+40.0%) | $76.26 M(+25.1%) |
| Sep 2007 | - | $60.98 M(+15.5%) |
| Jun 2007 | - | $52.80 M(+6.8%) |
| Mar 2007 | - | $49.44 M(+12.8%) |
| Dec 2006 | $171.10 M(-393.8%) | $43.83 M(-0.1%) |
| Sep 2006 | - | $43.88 M(+0.9%) |
| Jun 2006 | - | $43.51 M(+9.1%) |
| Mar 2006 | - | $39.88 M(-119.8%) |
| Dec 2005 | -$58.23 M(-134.6%) | -$201.89 M(-499.1%) |
| Sep 2005 | - | $50.58 M(+4.2%) |
| Jun 2005 | - | $48.53 M(+8.9%) |
| Mar 2005 | - | $44.55 M(+3.3%) |
| Dec 2004 | $168.37 M(+6.9%) | $43.12 M(-6.3%) |
| Sep 2004 | - | $46.00 M(+12.0%) |
| Jun 2004 | - | $41.06 M(+7.5%) |
| Mar 2004 | - | $38.20 M(-0.6%) |
| Dec 2003 | $157.49 M(+9.4%) | $38.41 M(-10.9%) |
| Sep 2003 | - | $43.09 M(+15.0%) |
| Jun 2003 | - | $37.46 M(-2.7%) |
| Mar 2003 | - | $38.52 M(-2.6%) |
| Dec 2002 | $143.94 M(+33.7%) | $39.54 M(+2.1%) |
| Sep 2002 | - | $38.74 M(+9.1%) |
| Jun 2002 | - | $35.52 M(+17.9%) |
| Mar 2002 | - | $30.13 M(-11.4%) |
| Dec 2001 | $107.66 M(+27.3%) | $33.99 M(+18.1%) |
| Sep 2001 | - | $28.77 M(+20.6%) |
| Jun 2001 | - | $23.86 M(+13.5%) |
| Mar 2001 | - | $21.02 M(-27.3%) |
| Dec 2000 | $84.55 M(+45.0%) | $28.93 M(-5.1%) |
| Sep 2000 | - | $30.49 M(+65.4%) |
| Jun 2000 | - | $18.43 M(-2.9%) |
| Mar 2000 | - | $18.98 M(+50.6%) |
| Dec 1999 | $58.30 M(+14.8%) | $12.60 M(-23.2%) |
| Sep 1999 | - | $16.40 M(+14.7%) |
| Jun 1999 | - | $14.30 M(-9.5%) |
| Mar 1999 | - | $15.80 M(+16.2%) |
| Dec 1998 | $50.80 M(+25.1%) | $13.60 M(+3.0%) |
| Sep 1998 | - | $13.20 M(+3.1%) |
| Jun 1998 | - | $12.80 M(+12.3%) |
| Mar 1998 | - | $11.40 M(+11.8%) |
| Dec 1997 | $40.60 M(-1.9%) | $10.20 M(+2.0%) |
| Sep 1997 | - | $10.00 M(-2.9%) |
| Jun 1997 | - | $10.30 M(0.0%) |
| Mar 1997 | - | $10.30 M(-6.4%) |
| Dec 1996 | $41.40 M(+18.3%) | $11.00 M(+3.8%) |
| Sep 1996 | - | $10.60 M(+7.1%) |
| Jun 1996 | - | $9.90 M(0.0%) |
| Mar 1996 | - | $9.90 M(+16.5%) |
| Dec 1995 | $35.00 M(-33.2%) | $8.50 M(-1.2%) |
| Sep 1995 | - | $8.60 M(-3.4%) |
| Jun 1995 | - | $8.90 M(-1.1%) |
| Mar 1995 | - | $9.00 M(-29.7%) |
| Dec 1994 | $52.40 M(+6.1%) | $12.80 M(+1.6%) |
| Sep 1994 | - | $12.60 M(-7.4%) |
| Jun 1994 | - | $13.60 M(+1.5%) |
| Mar 1994 | - | $13.40 M(-5.0%) |
| Dec 1993 | $49.40 M(+65.8%) | $14.10 M(+9.3%) |
| Sep 1993 | - | $12.90 M(+16.2%) |
| Jun 1993 | - | $11.10 M(-1.8%) |
| Mar 1993 | - | $11.30 M(+34.5%) |
| Dec 1992 | $29.80 M(+76.3%) | $8.40 M(+5.0%) |
| Sep 1992 | - | $8.00 M(+19.4%) |
| Jun 1992 | - | $6.70 M(0.0%) |
| Mar 1992 | - | $6.70 M(+17.5%) |
| Dec 1991 | $16.90 M(+103.6%) | $5.70 M(+29.5%) |
| Sep 1991 | - | $4.40 M(+18.9%) |
| Jun 1991 | - | $3.70 M |
| Dec 1990 | $8.30 M | - |
FAQ
- What is Regeneron Pharmaceuticals annual total expenses?
- What is the all time high annual total expenses for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual total expenses year-on-year change?
- What is Regeneron Pharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly total expenses year-on-year change?
What is Regeneron Pharmaceuticals annual total expenses?
The current annual total expenses of REGN is $10.11 B
What is the all time high annual total expenses for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual total expenses is $10.11 B
What is Regeneron Pharmaceuticals annual total expenses year-on-year change?
Over the past year, REGN annual total expenses has changed by +$1.23 B (+13.80%)
What is Regeneron Pharmaceuticals quarterly total expenses?
The current quarterly total expenses of REGN is $2.79 B
What is the all time high quarterly total expenses for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly total expenses is $2.79 B
What is Regeneron Pharmaceuticals quarterly total expenses year-on-year change?
Over the past year, REGN quarterly total expenses has changed by +$353.80 M (+14.55%)